Precise-target rTMS to relieve motor symptoms of tardive dyskinesia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center, double-blind, randomized, placebo-controlled interventional trial applies precisely localized rTMS to motor-related brain regions in adults with tardive dyskinesia. Participants are randomized to active rTMS or sham stimulation and followed for changes in motor symptom severity and safety outcomes. Motor symptoms will be measured with established clinical rating scales and adverse events monitored throughout the treatment and follow-up period. Key exclusions include other movement disorders, significant focal brain lesions, epilepsy, and implanted metallic or electronic devices.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (1) Age between 18 and 65 years; (2) Patients whose diagnosis is consistent with the tardive dyskinesia (TD) diagnostic criteria defined by the Schooler-Kane criteria, with a disease duration of at least 3 months before screening, and a history of treatment with dopamine receptor antagonists for at least 3 months (a minimum of 1 month for patients aged ≥ 60 years); other diseases that may cause involuntary movements are excluded

Exclusion Criteria:(1) Diagnosed with movement disorders other than tardive dyskinesia (TD); (2) A history of focal brain injury or severe leukoencephalopathy (Fazekas grade 3 or higher) identified on previous head MRI/CT; (3) A personal history of epilepsy, unexplained loss of consciousness, or current use of anticonvulsant medications for seizure management; (4) Presence of metallic medical devices in the body (e.g., cardiac pacemakers, cochlear implants), other metallic foreign bodies, or any electronic devices implanted in the body; or having other contraindications to repetitive Transcranial Magnetic Stimulation (rTMS); (5) Presence of contraindications to MRI scanning, such as having metallic implants in the body or claustrophobia

\-

Where it's running

• Peking University Sixth Hosptial
  Beijing, China Recruiting

Study contacts

• Study coordinator: bingyan xie
• Email: xie@bjmu.edu.cn
• Phone: 18715644290

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• NBI-1065890 versus placebo for adults with tardive dyskinesia

  This trial will test if NBI-1065890 reduces involuntary movements in adults with tardive dyskinesia compared with a placebo.

  Recruiting at 18 sites Phase 2 Neurocrine Biosciences · Bryant, Arkansas and 17 other locations · NCT07365462

• Valbenazine for adults with tardive dyskinesia who remain symptomatic on or after a VMAT2 inhibitor

  This trial will test whether valbenazine reduces involuntary movements in adults with tardive dyskinesia who still have symptoms while taking or after stopping a VMAT2 inhibitor.

  Recruiting at 19 sites Phase 4 Neurocrine Biosciences · Bryant, Arkansas and 18 other locations · NCT07105111

• Deutetrabenazine for Tardive Dyskinesia in IDD

  This study tests whether deutetrabenazine helps reduce tardive dyskinesia in people with intellectual and developmental disabilities who have not previously received this treatment.

  Recruiting Phase 4 University Hospitals Cleveland Medical Center · Cleveland, Ohio · NCT06997198

• Low-frequency rTMS to reduce belly pain in diarrhea-predominant IBS

  This trial tests whether low-frequency repetitive transcranial magnetic stimulation (rTMS) to a brain region can reduce visceral (belly) pain in adults with IBS-D.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT06757491

• Repetitive transcranial magnetic stimulation to improve post-surgery thinking and memory in older adults

  This trial will test whether repetitive transcranial magnetic stimulation (rTMS) given around the time of surgery helps older adults with mild-to-moderate cognitive impairment keep their thinking and memory after non-cardiac operations.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality and 2 other locations · NCT06482749

• Smoking cessation treatment for schizophrenia patients using varenicline

  This study is testing if the smoking cessation drug varenicline can help people with schizophrenia quit smoking while also managing their movement side effects from antipsychotic medications.

  Recruiting Phase 4 Corporal Michael J. Crescenz VA Medical Center · Philadelphia, Pennsylvania · NCT03495024

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.